Newscast – Page 164 – media

Merck buys into KalVista and its DME candidate

Shares in KalVista Pharmaceuticals have surged on news of a deal with Merck & Co potentially worth more than $750 million. Under the deal, Merck, which is known as MSD outside of the US and Canada, is paying KalVista $37 million upfront and taking a 9.9 percent stake in the firm in return for access to its experimental diabetic macular oedema drug KVD001.
- Source: Pharmatime
- 649
- October 12, 2017
diabetic macular Market Views oedema
FDA grants orphan drug status to UniQure’s Huntington’s Disease treatment

Dutch biotech UniQure has won orphan drug designation (ODD) for its investigational treatment for Huntington’s Disease, a rare, inherited neurodegenerative disorder that leads to loss of muscle coordination, behavioural abnormalities and cognitive decline.
- Source: 4-traders
- 822
- October 12, 2017
Huntington’s Disease neurodegenerative New Approvals ODD
Ebola vaccine tests hailed a success

The worst Ebola virus disease outbreak in history ended in 2016 after infecting 28,600 people and killing about 11,300 worldwide.
- Source: medicalxpress
- 1,246
- October 11, 2017
Ebola Market Views vaccine
Nanopatch polio vaccine delivers

Efforts to rid the world of polio have taken another significant step, thanks to research led by University of Queensland bioscience experts and funding from the World Health Organisation (WHO).
- Source: sciencedaily
- 694
- October 11, 2017
polio Researches WHO
Roche secures FDA approval for Zika virus screening test

Roche has secured approval from the US Food and Drug Administration (FDA) for its cobas Zika test to detect RNA of the Zika virus in human plasma samples.
- Source: medicaldevice-network
- 743
- October 11, 2017
FDA New Approvals plasma Zika
Magenta Medical, Developer of Novel Heart Failure Therapies, Secures $15 Million in Series B Financing

Magenta Medical was founded in October, 2012 by Prof. Ehud Schwammenthal and Mr. Yosi Tuval, Magenta Medical is developing novel therapeutic approaches to the management and treatment of Acute Heart Failure.
- Source: Infomeddnews
- 488
- October 11, 2017
Acute Heart Failure Market Views therapeutic
Synaptive Medical introduces new surgical robotic device

Canadian firm Synaptive Medical has introduced its second-generation, high-powered Modus V digital microscope that has a robotic arm to aid neurosurgery.
- Source: medicaldevice-network
- 640
- October 11, 2017
Company Insight microscope Modus V neurosurgery
AstraZeneca’s Tagrisso Gets Breakthrough Therapy Designation

AstraZeneca announced that the FDA has granted Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the first-line treatment of patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
- Source: finance.yahoo
- 645
- October 10, 2017
Company Insight EGFR FDA New Approvals NSCLC
Alcon gets CE-Mark for new preloaded IOL delivery system

Novartis’ division Alcon has obtained CE-Mark for its AutonoMe preloaded intraocular lens (IOL) delivery system to accurately deliver the IOL into the capsular bag during cataract surgery. The AutonoMe system is preloaded with a new biomaterial called Clareon IOL that features an advanced design for sharp vision, low edge glare and enhanced optic clarity. With an automated CO2-powered delivery mechanism, the preloaded system is intended to enable accurate single-handed control of IOL placement. Alcon CEO Mike Ball said: “With the introduction of Clareon AutonoMe, we are proud to unveil our latest innovations to benefit doctors and their patients undergoing cataract surgery. “Clareon AutonoMe builds upon the comprehensive legacy of AcrySof by offering cataract surgeons easy, intuitive control of IOL delivery with the newest optic material.” “The intuitive and easy-to-use device is expected to simplify the procedure and minimise surgical time.” The intuitive and easy-to-use device is expected to simplify the procedure ...
- Source: medicaldevice-network
- 599
- October 10, 2017
cataract Company Insight IOL New Approvals
Cardiologs raises $6m in Series A to support ECG Analysis Platform

Cardiologs Technologies said this week it raised $6.4 million in a Series A round of financing to support accelerated commercialization of its Cardiologs ECG Analysis Platform in the US and Europe.
- Source: Massdevice
- 529
- October 10, 2017
Cardiologs Market Views Series

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.